CLINICAL EVALUATION OF AC-1370 IN THE FIELD OF RESPIRATORY TRACT INFECTIONS

Abstract

The effect of AC-1370 were clinically evaluated in 9 cases with respiratory tract infections (6 cases of chronic bronchitis, 2 cases of pneumonia and one of lower respiratory tract infection with lung cancer). AC-1370 was administered 1g twice a day with drip infusion. Three cases among 6 with chronic bronchitis were those which were not effective on previously administered anti-bacterial agent. The case with lower respiratory tract infection was combined with lung cancer in terminal stage.
The results of clinical response were good in 4 cases and poor in 2 cases among 6 patients with chronic bronchitis, good in all 2 cases with pneumonia and poor in one case with lower respiratory tract infection. The effective rate in total was 67%.
As to the side effect, the slight and transient elevation of serum BUN and creatinine was observed in one case, but there is no other abnormality in patient's symptom and laboratory findings.
From the results, it was considered that AC-1370 would be expected to be useful for the treatment of patients with common lower respiratory tract infections.